Major histocompatibility complex class I presenting MUC1 epitopes (MHC-I/MUC1)

Major histocompatibility complex class I presenting MUC1 epitopes refers to the molecular complex formed when peptides derived from the Mucin 1 (MUC1) protein are processed and displayed on the cell surface by MHC class I molecules, most commonly HLA-A*02:01 (PubMed: 9151710). MUC1 is a transmembrane glycoprotein that is significantly overexpressed and aberrantly glycosylated in a wide range of epithelial malignancies, including breast, lung, and pancreatic cancers (UniProt: P15941). In these tumor cells, the altered processing of MUC1 generates unique peptide sequences that are presented to the immune system, serving as tumor-associated antigens (PubMed: 22431891). These complexes are specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes, making them a primary target for cancer vaccines and adoptive T-cell therapies (PubMed: 21854210). Therapeutic agents like Tecemotide and TG4010 are designed to stimulate the patient's immune system to recognize these specific MUC1 epitopes, thereby inducing a targeted anti-tumor response (PubMed: 26711545). However, because MUC1 is also expressed at lower levels on the apical surface of normal epithelial tissues, a major therapeutic challenge involves ensuring high specificity to avoid on-target, off-tumor toxicity.

Other names

HLA-MUC1 complexMUC1 peptide-MHC class I complexMUC1-derived peptide-HLA complexpMHC (MUC1)HLA-A*02:01-MUC1 complex

Induction of MUC1-specific CD8+ T-cell mediated cytotoxicity through active vaccination or passive transfer of TCR-engineered T cells.